Other languages Evoke Pharma, Inc.

Equities

EVOK

US30049G2030

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-17 pm EDT			5-day change	1st Jan Change
0.465 ^USD	-1.04%		+0.87%	-55.73%

May. 09	Certain Options of Evoke Pharma, Inc. are subject to a Lock-Up Agreement Ending on 9-MAY-2024.	CI
May. 09	Certain Common Stock of Evoke Pharma, Inc. are subject to a Lock-Up Agreement Ending on 9-MAY-2024.	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Evoke Pharma, Inc. Announces Board Changes as of March 31, 2024	Mar. 21
Evoke Pharma, Inc. Announces Chief Executive Officer Changes as of March 31, 2024	Mar. 21
Evoke Pharma, Inc. Provides Earnings Guidance for 2024	Mar. 14
Evoke Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14
Evoke Pharma Prices Underwritten Public Offering	Feb. 09
Evoke Pharma Says FDA Lists Latest US Patent for Gimoti in Orange Book	Nov. 27
Evoke Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Evoke Pharma, Inc. Provides Summary of Real-World Data on the Positive Impact of GIMOTI	Nov. 01
Evoke Pharma, Inc. Enters into Sixth Amendment to Lease with SB Corporate Centre III-IV, LLC	23-10-12
Evoke Pharma, Inc. Receives Notice of Allowance from U.S. Patent and Trademark Office for GIMOTI	23-09-14
Evoke Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Evoke Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
Evoke Pharma Patent Added To US FDA Orange Book Of Drug Products	23-05-01
Evoke Pharma, Inc. Announces United States Patent and Trademark Office Issues US Patent No. 11,628,150 Under the Title Nasal Formulations of Metoclopramide	23-04-20
Evoke Pharma Says US Patent and Trademark Office Grants Formulation Patent Covering GIMOTI Nasal Spray	23-04-20
Evoke Pharma's Q4 Loss per Share Narrows, Revenue Gains	23-03-21
Evoke Pharma, Inc. Provides Revenue Guidance for 2023	23-03-21
Evoke Pharma, Inc. Auditor Raises 'Going Concern' Doubt	23-03-20
Evoke Pharma, Inc. Announces Executive Changes	23-02-13
Evoke Pharma Says Joint Stipulation of Dismissal Filed in Gimoti Patent Infringement Case Involving Teva Pharmaceuticals	23-01-30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Evoke Pharma, Inc.

Equities

EVOK

US30049G2030

Other languages

Filters